BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250404T133000
DTEND;TZID=Europe/Vienna:20250404T143000
DTSTAMP:20260421T220533
CREATED:20241017T080415Z
LAST-MODIFIED:20250326T095143Z
UID:1928-1743773400-1743777000@esmit.eanm.org
SUMMARY:Radioiodine-Refractory Thyroid Cancer - Is it Time to Change the Definition in the Light of Novel Redifferentiation Therapies?
DESCRIPTION:This webinar explores the perspectives on radiorefractory thyroid cancer through two presentations. In the first talk the speaker challenges current diagnostic frameworks and proposes a new vision that better reflects the evolving understanding of refractory thyroid cancer. The second presentation offers a comprehensive review of emerging approaches to restore iodine avidity in radiorefractory thyroid cancer\, highlighting recent clinical trials\, molecular targeting techniques\, and potential promising combination therapies. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo evaluate the current definition of radiorefractory thyroid cancer and identify its limitations in clinical practice\n\n\n\nTo learn new insights for radiorefractory thyroid cancer definition and their potential impact on treatment decisions\n\n\n\nTo learn current evidence-based redifferentiation strategies for restoring iodine avidity in radiorefractory thyroid cancer\n\n\n\nTo improve knowledge of redifferentiation mechanisms to develop personalized treatment plans for patients with radiorefractory thyroid cancer\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine physicians\, Endocrinologist\, Oncologist \n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nPetra PetranovicSpeaker \n\n\n\n\n\nMichael KreisslSpeaker \n\n\n\n\n\nLuca GiovanellaModerator \n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/radioiodine-refractory-thyroid-cancer-is-it-time-to-change-the-definition-in-the-light-of-novel-redifferentiation-therapies/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
END:VCALENDAR